




RealRate

PHARMACEUTICAL 2022

Matinas Biopharma Holdings Inc
Rank 161 of 471

MATINAS

BIOPHARMA



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Matinas Biopharma Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Matinas Biopharma Holdings Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Matinas Biopharma Holdings Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 342%, being 67% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	50,993
Cost of Goods Sold	0
Intangible Assets	4,354
Liabilities, Current	4,349
Liabilities, Non-Current	4,484
Other Assets	4,441
Other Compr. Net Income	-374
Other Expenses	0
Other Liabilities	0
Other Net Income	1,328
Other Revenues	156
Property and Equipment	1,538
Research and Development	14,583
Selling, General and Administrative Expense	10,185

Output Variable	Value in 1000 USD
Assets	61,326
Liabilities	8,833
Expenses	24,768
Revenues	156
Stockholders Equity	52,493
Net Income	-23,283
Comprehensive Net Income	-23,470
BaseVar	48,393
ECR before Limited Liability	259%
Economic Capital Ratio	342%